-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2020.10.28 Research and Development NEWS: Henrui Pharmaceuticals "Injection HR17020" to start clinical; Pfizer oral JAK1 inhibitors are eligible for FDA priority review; AstraZeneta Grady net update instructions approved by the National Drug Administration; Jiahe Bio submits inflexi single anti-biosynthic drug listing application ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) The National Institutes of Health suspended a clinical trial of Lilly's anti-SARS-CoV-2 antibody LY-CoV555 in hospitalized COVID-19 patients before the trial of new crown antibodies was suspended.
reason is that LY-CoV555 treatment interventions are less likely to achieve clinical value in inpatient populations.
Hengrui Medicine "injection with HR17020" started clinical 27, Insight database shows that Hengrui 2 classes of modified new drugs "injection HR17020" for the first time started clinical, its indication is: prevention of renal syndrome patients venous thromboembolism.
(Drug Approval) Pfizer's oral JAK1 inhibitor has been approved for FDA Priority Review Pfizer announced today that the FDA has accepted the company's application for abrocitinib's new drug and granted it priority review eligibility.
Abrocitinib is a daily oral JAK1 inhibitor used to treat patients with moderate to severe endexual dermatitis over 12 years of age.
FDA is expected to respond in April next year.
AstraZeneta's Net Update Manual was approved by the National Drug Administration on the 28th, AstraZeneta announced that NMPA approved the renewal of AstraZeneta Down ® (common name: Dagley Net) China Manual, including DECLARE-TIMI 58 3 clinical research results of the relevant data.
DECLARE-TIMI 58 study shows that Dagrid is effective in reducing the risk of type 2 diabetes in adults with confirmed cardiovascular disease or multiple cardiovascular risk factors compared to placebos. Biosynthic drug listing application 27, Jia and Bio announced to NMPA has submitted the Invlixi monobiotic similar drug GB242 listing application, which is also the second application for listing after PD-1 antibody Jeno monoantigen Jia and Bio.
